LinkOPH

The ongoing takeover battle between Valeant and Allergan has shown no sign of closure, as further speculation of bids continue to flood the industry news wires.In April, William A. Ackman and Valeant first announced they would try to acquire Allergan; however, a series of events have since unfolded. From Allergan’s lawsuit against Valeant and Pershing Square, to a potential deal with Salix Pharmaceuticals, Healio.com has provided the latest coverage of this ongoing story.

Read more →

LONDON – At the European Society of Cataract and Refractive Surgeons meeting here, Marie-Jose Tassignon, MD, discusses a nanosecond YAG laser treatment for vitreous floaters. Tassignon describes three types of floaters: Category 1 are characterized as very dark floaters close to the retina, which can only be found using OCT analysis of the anterior interface; Category 2 are large, well suspended on vitreous strands, which are most easily treated; and Category 3 are floaters which are dispersed throughout the vitreous, which are the most difficult to treat.

Read more →

Topical travoprost monotherapy yielded a sustained reduction in 24-hour IOP for up to 5 years in patients with primary open-angle glaucoma, according to study findings.The 5-year, prospective study included 36 patients; 34 patients completed the study.

Read more →

WASHINGTON — During his keynote remarks at U.S. News & World Report’s Hospital of Tomorrow Forum, Gregory Sorensen, MD, cited an example from recent headlines to illustrate his point regarding the need for insurance companies to incentivize early, accurate diagnoses.“If you need a recent news event to help you think about that, think of the patient with Ebola in Texas,” Sorensen, CEO of Siemens Healthcare, said in his presentation at the U.S. News & World Report’s Hospital of Tomorrow Forum. “No one was rewarded for diagnosing it right; no one (Read more...)